Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATRIPCA: Pembrolizumab and Debio 1143 in Advanced Pancreatic and Colorectal Cancer
NCT03871959Phase 1Completed
- Sponsor
- Centre Léon Bérard
- Start
- Sep 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of xevinapant in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), sponsored by Centre Léon Bérard. Primary endpoints: Maximum Tolerated Dose at 21 days, Recommended Dose for Phase 2 at 21 days and 1 more. Started Sep 2019; status: completed.
02
Drugs
xevinapant
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03871959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871959.